Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma (Q44198069)

30 November 2017

title

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma (English)

1 reference

30 November 2017

Sharon Gordon

1 reference

30 November 2017

Miep H Helfrich

1 reference

30 November 2017

Hamdi I A Sati

1 reference

30 November 2017

Michael Greaves

1 reference

30 November 2017

Stuart H Ralston

1 reference

30 November 2017

Dominic J Culligan

1 reference

30 November 2017

Richard L Soutar

1 reference

30 November 2017

Michael J Rogers

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

British Journal of Haematology

30 November 2017

published in

1 reference

30 November 2017

volume

119

1 reference

30 November 2017

1 reference

30 November 2017

page(s)

475-483

1 reference

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

The potential of farnesyltransferase inhibitors as cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Anti-myeloma activity of pamidronate in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Bisphosphonates--mechanisms of action in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

Detection of myeloma cells in the peripheral blood by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2002.03824.X

10.1046/J.1365-2141.2002.03824.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference